Protagenic Therapeutics Bolsa (NASDAQ: PTIX)

Últimas noticias sobre Protagenic Therapeutics (NASDAQ:PTIX) Bolsa

Protagenic Therapeutics

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics Inc

<h3>Gainers</h3>
<ul>
<li>Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) stock moved upwards by 24.3% to $4.3 during Monday's pre-market session. The market value of their outstanding shares is at $516.1 million. </li>
<li>Traws Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) stock increased by 16.2% to $6.67. The company's market cap stands at $20.1 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) shares increased by 14.28% to $2.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 13.81% to $10.3. The market value of their outstanding shares is at $11.0 million. As per the news, the Q2 earnings report came out today. </li>
<li>BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) stock increased by 13.01% to $9.12. The company's market cap stands at $152.1 million. </li>
<li>AnaptysBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares rose 9.82% to $35.0. The market value of their outstanding shares is at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares fell 20.8% to $0.23 during Monday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares declined by 11.66% to $4.55. The company's market cap stands at $284.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 11.28% to $0.55. The company's market cap stands at $2.4 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $38.5 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock declined by 10.13% to $0.57. The company's market cap stands at $7.6 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares decreased by 7.5% to $0.66. The market value of their outstanding shares is at $4.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADXN

ANAB

BNOX

BWAY

CRVS

ENSC

ESLA

PRME

PTIX

THAR

TRAW

VERO

12 Health Care Stocks Moving In Monday's Pre-Market Session

Shares of Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose sharply in today's pre-market trading after the company entered into debt-for-equity exchange agreements and <a href="https://www.benzinga.com/quote/XCUR/news">regained Nasdaq compliance.</a>
Exicure shares jumped 49.3% to $2.39 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 94.4% to $4.94 in pre-market trading. NuCana presented final data from Phase 2 Nutide:701 study at ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.</li>
<li>Dermata Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) rose 73.4% to $2.74 in today's pre-market trading after gaining around 7% on Tuesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) gained 53.1% to $2.68 in the pre-market trading session. Agape ATP shares jumped over 20% on Friday after the company announced it entered into a strategic collaboration with Xiamen Photons Solar Technology that focusing on developing solar photovoltaic mounting systems in ASEAN countries.</li>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) gained 22.1% to $9.22 in pre-market trading after jumping around 72% on Friday. The company announced the pricing of a $4.5 million public offering of 1.22 million shares and warrants.</li>
<li>iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) rose 20.1% to $20.05 in pre-market trading. iTeos Therapeutics announced follow-up interim data from GALAXIES Lung-201 Phase 2 platform study sponsored by GSK, for Belrestotug+Dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer.</li>
<li>IO Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) rose 18.2% to $0.8874 in pre-market trading. IO Biotech announced data from Phase 2 Basket trial of IO102-IO103, therapeutic cancer vaccine candidate, in combination with Merck&#8217;s Keytruda at the 2024 ESMO Congress.</li>
<li>Yunji Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) gained 14.3% to $2.48 in pre-market trading after gaining 12% on Friday.</li>
<li>Adagene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) shares rose 13.7% to $ 3.97 in pre-market trading. Adagene announced new ADG126 clinical data from ongoing Phase 1b/2 trial of SAFEbody Plus Keytruda Combo Presented at the ESMO Congress.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 9% to $0.38 in pre-market trading after gaining around 6% on Friday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) fell 40.1% to $1.00 in pre-market trading after gaining 9% on Friday.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares dipped 21.8% to $4.65 in pre-market trading after surging 143% on Friday.</li>
<li>Presidio Property Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SQFT#NASDAQ">SQFT</a>) fell 20.4% to $0.55 in pre-market trading.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 16.7% to $0.13 in pre-market trading. Psyence Biomedical announced the receipt of staff delisting determination from Nasdaq.</li>
<li>Edgio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGIO#NASDAQ">EGIO</a>) shares declined 14.7% to $1.33 in pre-market trading after dipping 27% on Friday.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 11.6% to $0.48 in pre-market trading after dipping around 67% on Friday.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares fell 11.4% to $0.7001 in pre-market trading after declining 9% on Friday.</li>
<li>Purple Biotech Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) shares declined 11.2% to $0.3438 in pre-market trading after gaining 7% on Friday.</li>
<li>LeddarTech Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LDTC#NASDAQ">LDTC</a>) fell 9.4% to $0.4001 in today's pre-market trading.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) declined 8.2% to $24.60 in pre-market trading after gaining around 5% on Friday.</li>
</ul>
<a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Now Read This: </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40860420/jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics">Jim Cramer: &#8216;Hold On&#8217; To Builders FirstSource, &#8216;Here&#8217;s The Problem&#8217; With Viking Therapeutics</a></li>
</ul>

News

Pre-Market Outlook

Markets

Trading Ideas

ADAG

ATPC

DRMA

EGIO

ENTO

IOBT

ITOS

LDTC

NCNA

PPBT

SQFT

TNON

XCUR

Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket

Shares of Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) rose sharply in today's pre-market trading reported better-than-expected financial results for the <a href="https://www.benzinga.com/quote/CSBR/earnings">first quarter on Wednesday.</a>
The company reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of a loss of $0.3 per share.
Champions Oncology shares jumped 13.5% to $4.55 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) gained 89.4% to $1.61 in pre-market trading. HRT Financial LP acquired a new stake in Smart for Life.</li>
<li>Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) rose 58% to $1.58 in today's pre-market trading.</li>
<li>N2OFF, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>) gained 42.4% to $0.4273 in the pre-market trading session after the company announced a potential 10% increase in capacity for its Solar PV Joint Venture Project with Solterra Renewable Energy.</li>
<li>NETGEAR, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTGR#NASDAQ">NTGR</a>) shares gained 27.8% to $20.37 in pre-market trading after the company disclosed a settlement agreement with TP-Link Systems and raised its third-quarter revenue guidance.</li>
<li>Perfect Moment Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#NASDAQ">PMNT</a>) gained 18.6% to $1.15 in pre-market trading after declining around 8% on Wednesday.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) gained 14.4% to $0.1419 in pre-market trading.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) rose 13.8% to $0.1983 in pre-market trading after dipping 14% on Wednesday. Pineapple Energy recently entered into exchange agreements to swap Series A preferred stock and warrants for Series C preferred stock, convertible at $0.45 per share.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 8.7% to $3.94 in pre-market trading. ImmunityBio recently presented long-term overall survival data in non-small cell lung cancer patients and announced registrational intent Phase 3 trials with ANKTIVA and checkpoint immunotherapy at the World Conference on Lung Cancer.</li>
<li>Applied Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) gained 5% to $5.47 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) fell 61.7% to $5.02 in pre-market trading after dipping more than 35% on Wednesday.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) fell 48.4% to $0.4128 in pre-market trading. Syra Health priced its $2.1 million public offering with shares and warrants priced at $0.64 each.</li>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares dipped 40% to $1.02 in pre-market trading. Telesis Bio shares dipped 55% on Wednesday after the company announced that it has notified the Nasdaq Stock Market of its decision to delist.</li>
<li>CN Energy Group. Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNEY#NASDAQ">CNEY</a>) shares fell 25.9% to $1.03 in pre-market trading. CN Energy Group received Nasdaq notice that it is currently not in compliance with certain requirements under relevant listing rules.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares declined 17.7% to $2.59 in pre-market trading after the company announced a $5.35 million private placement.</li>
<li>FTC Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) shares fell 16.4% to $0.3841 in pre-market trading. FTC Solar shares jumped 104% on Wednesday after the company announced that it has been selected by Strata Clean Energy to supply approximately 500 megawatts of its Voyager 2P solar tracker technology for multiple project sites in the U.S. and will be the preferred 2P solar tracker supplier over a three-year initial term.</li>
<li>iSpecimen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) fell 14.5% to $0.21 in today's pre-market trading after the company announced a 1-for-20 reverse stock split.</li>
<li>Oxford Industries, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) shares declined 10.3% to $75.02 in pre-market trading after the company reported weaker-than-expected earnings and sales results for the second quarter. The company said it sees FY24 net sales of $1.51 billion to $1.54 billion and adjusted earnings of $7 to $7.30 per share.</li>
<li>Cadrenal Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares fell 8.6% to $7.73 in pre-market trading after jumping around 18% on Wednesday.</li>
<li>BeiGene, Ltd.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGNE#NASDAQ">BGNE</a>) declined 6.8% to $196.80 in pre-market trading after gaining around 7% on Wednesday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

APLT

BGNE

CNEY

CSBR

CVKD

FTCI

IBRX

ISPC

NITO

NTGR

PEGY

PMNT

RYDE

SMFL

SYRA

TBIO

Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 118.4% to $1.07 during Thursday's regular session. The market value of their outstanding shares is at $25.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 46.79% to $1.38. The company's market cap stands at $203.5 million. </li>
<li>Altamira Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTO#NASDAQ">CYTO</a>) shares increased by 29.37% to $1.85. The company's market cap stands at $4.1 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock rose 23.44% to $0.84. The company's market cap stands at $21.9 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) stock increased by 23.04% to $0.62. The market value of their outstanding shares is at $73.8 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock moved upwards by 22.39% to $0.71. The market value of their outstanding shares is at $25.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares fell 17.8% to $1.89 during Thursday's regular session. The company's market cap stands at $5.2 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares fell 16.92% to $0.09. The market value of their outstanding shares is at $14.1 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares declined by 16.08% to $1.51. The company's market cap stands at $6.6 million. </li>
<li>Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) shares decreased by 15.51% to $50.05. The market value of their outstanding shares is at $5.2 billion. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares fell 15.5% to $2.4. The market value of their outstanding shares is at $22.1 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>DermTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) stock declined by 14.05% to $0.36. The company's market cap stands at $12.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYTK

CYTO

DMTK

HLTH

ONMD

PIII

RENB

SABS

SILO

12 Health Care Stocks Moving In Thursday's Intraday Session

General

Protagenic Therapeutics shares are trading lower. The company reported safety data from the single dose portion of its Phase 1 trial involving PT00114.

No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence

Biotech

Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114

Protagenic Therapeutics Completes Enrollment In Single Dose Portion Of Phase 1 Of PT00114 Stress Disorder Trial

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares rose 75.3% to $1.49 during Friday's pre-market session. The company's market cap stands at $245.2 million. </li>
<li>Cryo-Cell International (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CCEL#AMEX">CCEL</a>) shares increased by 27.94% to $9.98. The market value of their outstanding shares is at $80.8 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares moved upwards by 18.33% to $0.71. The market value of their outstanding shares is at $17.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 16.79% to $0.04. The company's market cap stands at $3.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) stock increased by 15.82% to $4.99. The market value of their outstanding shares is at $11.1 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock increased by 11.47% to $2.36. The company's market cap stands at $4.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares fell 15.6% to $2.05 during Friday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares decreased by 15.58% to $2.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares declined by 13.85% to $0.25. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) stock fell 12.79% to $0.34. The company's market cap stands at $2.4 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) shares decreased by 12.13% to $0.79. The company's market cap stands at $16.8 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares decreased by 12.03% to $1.38. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACON

CCEL

FRES

GNPX

MBRX

NUWE

PCSA

TVGN

VINC

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Aclarion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock moved upwards by 43.18% to $2.32. The market value of their outstanding shares is at $6.6 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) shares moved upwards by 29.87% to $1.0. The market value of their outstanding shares is at $109.5 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 22.87% to $0.72. The company's market cap stands at $33.9 million. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock increased by 21.64% to $1.63. The company's market cap stands at $6.6 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares moved upwards by 18.93% to $4.14. The market value of their outstanding shares is at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 33.1% to $1.54 during Thursday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Organogenesis Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) stock decreased by 22.32% to $2.31. The market value of their outstanding shares is at $305.4 million. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) shares decreased by 16.35% to $1.74. The market value of their outstanding shares is at $3.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 14.31% to $1.4. The market value of their outstanding shares is at $6.2 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares fell 14.14% to $3.95. The company's market cap stands at $41.8 million. </li>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 13.68% to $1.01. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AONC

BACK

CYCC

EYEN

INVO

ORGO

POAI

XYLO

<h3>Gainers</h3>
<ul>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) shares rose 33.6% to $0.8 during Tuesday's regular session. The market value of their outstanding shares is at $65.7 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock increased by 29.81% to $6.4. The company's market cap stands at $5.4 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares increased by 24.67% to $0.14. The market value of their outstanding shares is at $5.5 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares increased by 23.88% to $1.55. The company's market cap stands at $6.8 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) stock moved upwards by 23.21% to $1.38. The market value of their outstanding shares is at $19.3 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares moved upwards by 20.4% to $1.77. The company's market cap stands at $40.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares decreased by 52.3% to $3.51 during Tuesday's regular session. The company's market cap stands at $96.0 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock decreased by 16.97% to $2.94. The market value of their outstanding shares is at $117.9 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock decreased by 13.57% to $0.16. The company's market cap stands at $44.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock declined by 13.25% to $12.51. The market value of their outstanding shares is at $461.6 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares decreased by 12.74% to $1.26. The market value of their outstanding shares is at $1.2 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock fell 12.49% to $0.26. The company's market cap stands at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

BIMI

JAGX

Kintara Therapeutics, Inc. - Common Stock

KTRA

NKGN

PALI

PRTG

RZLT

SBFM

VNRX

12 Health Care Stocks Moving In Tuesday's Intraday Session

Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit
NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, Chief Operating Officer, will present a talk on PT00114, the company's promising new drug candidate, at the Peptide Based Therapeutic Summit in Boston.
Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment," Dr. Slee's talk will focus on the groundbreaking structure of PT00114, designed to efficiently cross the blood-brain barrier and unlock new potential in treating serious neuro-psychiatric conditions. He will share compelling preclinical data and insights into the ongoing clinical safety trial that underline the therapeutic's efficacy and innovative approach.
Event Details:
Topic: Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment Speaker: Dr. Andrew Slee, PhD, COO of Protagenic Therapeutics Date &amp; Time: 2:00 pm EST, April 23, 2024 Location: Hilton Boston Logan Airport, Boston, MA Talk Info: Speaker Agenda <a href="https://pr.report/ntEe2L6m">https://peptide-based-therapeutics-summit.com/speaker/andy-slee/</a>
About the Peptide Based Therapeutics Summit:
This premier event is planned to gather industry leaders to discuss the latest advancements in peptide therapy, focusing on enhancing drug design, delivery, and therapeutic efficacy across a variety of diseases. This inaugural summit will cover the latest strategies in improving oral bioavailability and targeted cellular delivery, critical in the next generation of peptide therapeutics.

Protagenic Therapeutics' Peptide PT00114 To Be Highlighted At Boston Summit In Presentation Titled "Novel Blood-Brain Barrier Penetrating Peptide: Opening New Doors in Neuro-Psychiatric Treatment" On April 23, 2024

Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) reported quarterly losses of $(0.38) per share. This is a 171.43 percent decrease over losses of $(0.14) per share from the same period last year.

Earnings

Protagenic Therapeutics Q4 EPS $(0.38) Down From $(0.14) YoY

Protagenic Therapeutics FY23 EPS $(1.15) Down From $(0.82) YoY

<h3>Companies Reporting Before The Bell</h3>
&bull; Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is projected to report quarterly earnings at $0.92 per share on revenue of $213.43 million.
&bull; Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) is expected to report earnings for its fourth quarter.
&bull; Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $16.58 million.
&bull; Enservco (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ENSV#AMEX">ENSV</a>) is projected to report quarterly loss at $0.05 per share on revenue of $6.60 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; Milestone Scientific (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MLSS#AMEX">MLSS</a>) is likely to report earnings for its fourth quarter.
&bull; SPAR Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRP#NASDAQ">SGRP</a>) is estimated to report earnings for its fourth quarter.
&bull; Escalade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESCA#NASDAQ">ESCA</a>) is estimated to report earnings for its fourth quarter.
&bull; LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) is likely to report quarterly loss at $1.73 per share on revenue of $2.28 million.
&bull; Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) is projected to report earnings for its fourth quarter.
&bull; Crown ElectroKinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) is expected to report earnings for its fourth quarter.
&bull; LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) is estimated to report earnings for its fourth quarter.
&bull; DecisionPoint Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/DPSI#AMEX">DPSI</a>) is expected to report earnings for its fourth quarter.
&bull; Edible Garden AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) is estimated to report earnings for its fourth quarter.
&bull; Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) is expected to report earnings for its fourth quarter.
&bull; Terran Orbital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $32.81 million.
&bull; Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $105.82 million.
&bull; Vislink Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VISL#NASDAQ">VISL</a>) is estimated to report earnings for its fourth quarter.
&bull; Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) is projected to report quarterly loss at $0.30 per share on revenue of $2.82 million.
&bull; Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $4.27 million.
&bull; TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is projected to report quarterly loss at $0.69 per share on revenue of $5.45 million.
&bull; Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) is projected to report quarterly loss at $1.18 per share on revenue of $22.45 million.
<h3>Companies Reporting After The Bell</h3>
&bull; BurgerFi International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) is expected to report quarterly loss at $0.19 per share on revenue of $40.00 million.
&bull; AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is expected to report earnings for its fourth quarter.
&bull; PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) is expected to report quarterly earnings at $3.53 per share on revenue of $2.42 billion.
&bull; VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $9.37 million.
&bull; Motorsport Games (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSGM#NASDAQ">MSGM</a>) is estimated to report earnings for its fourth quarter.
&bull; Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) is estimated to report quarterly loss at $0.30 per share on revenue of $30 thousand.
&bull; OMNIQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMQS#NASDAQ">OMQS</a>) is likely to report quarterly loss at $0.26 per share on revenue of $16.35 million.
&bull; FlexShopper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FPAY#NASDAQ">FPAY</a>) is projected to report quarterly loss at $0.25 per share on revenue of $30.51 million.
&bull; Stryve Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNAX#NASDAQ">SNAX</a>) is estimated to report quarterly loss at $1.96 per share on revenue of $5.01 million.
&bull; Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) is expected to report quarterly loss at $0.34 per share on revenue of $12.40 million.
&bull; Eastside Distilling (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) is expected to report quarterly loss at $0.90 per share on revenue of $3.68 million.
&bull; BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is expected to report earnings for its fourth quarter.
&bull; SKYX Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) is likely to report quarterly loss at $0.08 per share on revenue of $21.12 million.
&bull; Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) is projected to report earnings for its fourth quarter.
&bull; Natural Gas Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGS#NYSE">NGS</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $30.30 million.
&bull; TOMI Environmental Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOMZ#NASDAQ">TOMZ</a>) is expected to report quarterly loss at $0.01 per share on revenue of $2.86 million.
&bull; Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) is likely to report quarterly loss at $1.77 per share on revenue of $700 thousand.
&bull; GSE Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVP#NASDAQ">GVP</a>) is likely to report quarterly loss at $0.81 per share on revenue of $12.07 million.
&bull; Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) is likely to report earnings for its fourth quarter.
&bull; Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) is projected to report earnings for its fourth quarter.
&bull; SHF Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) is likely to report earnings for its fourth quarter.
&bull; Ideanomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDEX#NASDAQ">IDEX</a>) is likely to report earnings for its fourth quarter.
&bull; American Strategic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYC#NYSE">NYC</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $16.53 million.
&bull; Zomedica (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is expected to report earnings for its fourth quarter.
&bull; Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) is estimated to report quarterly loss at $0.07 per share on revenue of $94.43 million.
&bull; Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $50.27 million.
&bull; IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is projected to report quarterly loss at $0.07 per share on revenue of $10.00 million.
&bull; Duos Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOT#NASDAQ">DUOT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $3.00 million.
&bull; Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $10.89 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACOR

AIRI

ASTS

BKYI

CRKN

DPSI

DUOT

EAST

EDBL

ENSV

ESCA

FPAY

GOEV

IDEX

IZEA

LASE

LGMK

LLAP

LMFA

MLSS

MSGM

MVST

NNOX

NXGL

OMER

OMQS

ONDS

PPSI

SACH

SGML

SGRP

SHF Holdings, Inc. - Class A Common Stock

SHFS

SKYX

SNAX

STSS

TLSI

TOMZ

VISL

VTSI

YTEN

Earnings Scheduled For April 1, 2024

Next clinical progress update expected in April 2024
NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related neuropsychiatric disorders. The company has reached another milestone by completing three out of five cohorts of healthy volunteers with PT00114, its synthetic version of the stress-regulating peptide TCAP, in a SAD Phase 1 clinical trial. Notably, PT00114 has shown excellent tolerability with no adverse safety findings during these ongoing Phase 1 studies. With promising preclinical efficacy in anxiety, depression, PTSD, and addiction models, PT00114 moves forward in clinical evaluation, representing a step toward potentially transformative therapies.
Key Highlights:
<ul>
<li>Safety Validation: Building on the low dose safety validation announced February 13th, PT00114 has now demonstrated safety at a medium dose of 500 micrograms administered subcutaneously in the third of five planned cohorts of subjects in the single dose portion of the Phase I trial. No adverse reactions were observed among subjects, consistent with the two lower dose cohorts (125 micrograms and 250 micrograms), with no reported injection site reactions or tolerability issues in the week following dosing. Based on preclinical pharmacology, PT00114 is expected to be administered once weekly via subcutaneous injection.</li>
<li>Clinical Protocol Progress: This marks progress in the ongoing Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD, or Generalized Anxiety Disorder. The company plans to enroll the final two cohorts into the single dose portion of the Phase 1 trial within the next month.</li>
<li>Comprehensive Approach: In addition to monitoring disease status, the trial incorporates biomarker assessments, including circulating cortisol levels, to measure initial treatment response. Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital, serves as the Principal Investigator in Protagenic's Phase 1/2a clinical trial with a basket design.</li>
<li>Strategic Collaboration: Axiom Real-Time Metrics, a CRO/Data Analytics firm, manages the clinical program.</li>
</ul>
About Protagenic Therapeutics, Inc.: Protagenic Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) is dedicated to pioneering therapeutics based on neuro-active peptides to alleviate the negative effects of stress and treat stress-related disorders such as anxiety, depression, PTSD, and addiction. For more information, visit <a href="https://pr.report/r4Z9M7Vv">www.protagenic.com</a>.
About PT00114: PT00114, a 41-amino-acid residue synthetic peptide, shows promise as a novel treatment for serious neuro-psychiatric conditions, including depression, anxiety, and PTSD. It is a synthetic form of the naturally occurring brain peptide TCAP, which counters the negative biochemical and behavioral effects of stress-induced brain hormones Corticotropin Releasing Factor and Arginine-Vasopressin. Among its benefits is the reduction of excessive circulating levels of cortisol often associated with various stressors.

Protagenic Therapeutics Successfully Concludes Third Cohort In Single Dose Portion Of Phase 1 Trial For Stress-Related Neuropsychiatric Disorders

Protagenic Therapeutics Announces Resolution Of Nasdaq Deficiency Notice

<h3>Gainers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock rose 142.3% to $0.11 during Tuesday's regular session. The company's market cap stands at $5.9 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares rose 54.65% to $6.31. The company's market cap stands at $215.0 million. </li>
<li>Apogee Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) shares rose 50.83% to $62.96. The market value of their outstanding shares is at $3.0 billion. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) shares rose 46.34% to $2.4. The market value of their outstanding shares is at $93.6 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares increased by 33.85% to $10.32. The company's market cap stands at $38.6 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares increased by 31.79% to $1.32. The company's market cap stands at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares fell 45.9% to $1.57 during Tuesday's regular session. The market value of their outstanding shares is at $1.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock declined by 24.71% to $1.58. The company's market cap stands at $28.1 million. The company's, Q4 earnings came out yesterday. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 22.34% to $0.8. The company's market cap stands at $4.9 million. </li>
<li>Kineta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KA#NASDAQ">KA</a>) stock decreased by 22.28% to $0.79. The market value of their outstanding shares is at $8.1 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock declined by 22.15% to $1.77. The market value of their outstanding shares is at $78.3 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) shares declined by 18.3% to $39.91. The market value of their outstanding shares is at $274.3 million. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APGE

BYSI

CMAX

EKSO

LIPO

OCEA

QNRX

SMLR

Protagenic Therapeutics Completes First Dose Escalation Step In Phase I Safety Clinical Trial For PT00114

<h3>Gainers</h3>
<ul>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock moved upwards by 93.8% to $4.09 during Wednesday's regular session. The company's market cap stands at $173.7 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock rose 89.48% to $0.48. The market value of their outstanding shares is at $6.2 million. </li>
<li>C4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) shares increased by 86.32% to $4.36. The company's market cap stands at $214.8 million. </li>
<li>Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) shares moved upwards by 81.84% to $0.06. The company's market cap stands at $12.1 million. </li>
<li>ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) shares increased by 35.38% to $28.66. The company's market cap stands at $4.7 billion. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock increased by 26.72% to $0.73. The company's market cap stands at $59.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares decreased by 21.7% to $0.8 during Wednesday's regular session. The company's market cap stands at $25.8 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) stock fell 19.84% to $0.65. The company's market cap stands at $16.0 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares fell 18.94% to $1.07. The company's market cap stands at $21.0 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock declined by 18.19% to $0.81. The market value of their outstanding shares is at $3.5 million. </li>
<li>Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) shares declined by 16.98% to $12.81. The company's market cap stands at $495.3 million. </li>
<li>Black Diamond Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDTX#NASDAQ">BDTX</a>) shares fell 15.26% to $2.44. The company's market cap stands at $126.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACAD

AVTX

BDTX

CCCC

RDHL

RSLS

STTK

12 Health Care Stocks Moving In Wednesday's Intraday Session

Protagonist Therapeutics, Inc. (&quot;Protagonist&quot; or the &quot;Company&quot;) announced details from five abstracts at the American Society of Hematology 2023 Annual Meeting, including an oral presentation with two-year follow up data from the Phase 2 REVIVE study with rusfertide, a mimetic of the natural hormone hepcidin with potential therapeutic value in the treatment of polycythemia vera (PV) and other disease indications. Copies of the presentations will be available on the&nbsp;<a href="https://pr.report/hRj2zZpM">Events and Presentations</a>&nbsp;section of the Protagonist website.

Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting

EYEN, BYSI and FENG among mid-day movers

Protagenic Therapeutics (PTIX) has issued an announcement. In a positive turn for investors, a company has successfully addressed its previous Nasd...

Protagenic Therapeutics Regains Nasdaq Compliance, Boosts Confidence

Protagenic Therapeutics GAAP EPS of -$1.15

Protagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Protagenic Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptix-stock-quote/">PTIX</a>) just reported results for the fourth quarter of 2023.<ul><li>Protagenic Therapeutics reported earnings per share of -38 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/ptix-stock-earnings-protagenic-therapeutics-for-q4-of-2023/">PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023

KOPN, BTCM and CETX among mid-day movers

Jaguar Health, Altamira Therapeutics,Erasca among healthcare movers

Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Protagenic Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptix-stock-quote/">PTIX</a>) just reported results for the first quarter of 2024.<ul><li>Protagenic Therapeutics reported earnings per share of -39 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/ptix-stock-earnings-protagenic-therapeutics-for-q1-of-2024/">PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Protagenic Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptix-stock-quote/">PTIX</a>) just reported results for the second quarter of 2024.<ul><li>Protagenic Therapeutics reported earnings per share of -36 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptix-stock-earnings-protagenic-therapeutics-for-q2-of-2024/">PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

Protagenic Therapeutics

Noticias

Últimas noticias sobre Protagenic Therapeutics (NASDAQ:PTIX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL